Clinical Trial Update: FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating FOLFIRI as second-line chemotherapy for metastatic esophageal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)

Snippet

Sponsor: Yuhong Li | Conditions: Advanced Esophageal Carcinoma | Phase 2 | Status: COMPLETED